Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in non-1p/19q deleted anaplastic glioma
NCT00626990Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2007
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of temozolomide in anaplastic glioma, sponsored by European Organisation for Research and Treatment of Cancer. Started Dec 2007; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
anaplastic glioma
Beyond the preview
Go deeper on NCT00626990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626990.